Audio Journal of Oncology Podcast

Hope S. Rugo, MD; SABCS 2025: Selective Estrogen Degrader Giredestrant Brings Clinically Meaningful Improvements in Metastatic Breast Cancer: evERA Breast Cancer Trial

An interview with:

Hope S. Rugo, MD, Director, Women’s Cancers Program; Division Chief, Breast Medical Oncology; Professor, Department of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA

SAN ANTONIO, USA—Further improvements in hormone therapy for ER-positive breast cancer were on display at the San Antonio Breast Cancer Symposium where results from the Phase III evERA Breast Cancer trial were discussed.  The study investigated the use o...

Othman Al-Sawaf MD PhD; ASH 2025: Fixed-Duration Targeted Combinations As Effective as Extended Monotherapy for Patients with Untreated Chronic Lymphocytic Leukemia

An interview with:

Othman Al-Sawaf MD PhD, Hematologist & Medical Oncologist, University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany 

ORLANDO, USA— Early data from the CLL17 international, randomized phase three trial for patients with previously untreated chronic lymphocytic leukemia found that fixed-duration treatment with either venetoclax plus obinutuzumab or venetoclax plus ibrutinib were non-inferior to continuous treatment with ibrutinib and may therefore become the preferred treatment option.

Othman Al-Sawaf MD...

Juan Du MD PhD,  ASH 2025: Dual Targeted FasTCAR-T Therapy brings Deep, Durable Responses to Patients with Newly Diagnosed Multiple Myeloma

An interview with:

Juan Du MD PhD, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

ORLANDO, USA—Patients with newly diagnosed multiple myeloma had deep, long lasting responses to initial therapy with a new CAR T-cell therapy targeting both B-cell maturation antigen (BCMA) and CD19 using the “FasTCAR-T” platform being tested in a phase one study. Lead author Juan Du MD PhD, from Ren Ji Hospital, and Jiao Tong Un...

Thorsten Kühn MD PhD; SABCS 2025: No Need for Axillary Node Dissection When Clinically Node-Positive Breast Cancers Convert to Node-Negative After Neoadjuvant Chemotherapy

An interview with:

Thorsten Kühn MD PhD, Head, Breast Center, Filderklinik, Stuttgart, Germany; Senior Consultant, University of Ulm; Chairman, European Breast Cancer Research Association of Surgical Trialists

SAN ANTONIO, USA— Breast cancers that convert from clinically node-positive to node-negative as a result of neoadjuvant chemotherapy, do not need axillary lymph node dissection, regardless of tumor type.

Less invasive axillary surgical staging procedures (such as sentinel node dissection and...

María-Victoria  Mateos; ASH 2025: Unprecedented Survival Benefits with BCMA/CD3 Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma: Majestec-3 Study Findings

An interview with:

María-Victoria  Mateos MD PhD, Hematologist and Myeloma Unit Director, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, and Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), CIBERONC, Salamanca, Spain.

ORLANDO, USA—Statistically significant improvements in progression-free and overall survival among patients with relapsed or refractory multiple myeloma were reported at the 2025 Annual Meet...

Erika Hamilton MD; 2025 SABCS: Small Molecule HER2 Inhibitor Tucatinib Improves Progression Free Survival in Patients with HER2-positive Metastatic Breast Cancer: in HER2CLIMB-05 Trial

An interview with:

Erika Hamilton MD, Breast Cancer Research Program Leader, Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.

SAN ANTONIO, USA—Adding the small-molecule tyrosine kinase inhibitor tucatinib to a combination of trastuzumab and pertuzumab as first-line maintenance therapy in patients with HER2-positive metastatic breast cancer improved progression-free survival and, according to research reported at the   2025San Antonio Breast Cancer Symposium, did not resu...

Wojciech Jurczak MD PhD; ASH 2025: Big Study Suggests Non-Covalent BTK Inhibitor Pirtobrutinib Could be New Standard-of-Care for Patients with Untreated Chronic Lymphocytic Leukemia

An interview with:

Wojciech Jurczak MD PhD, Professor of Hematology, National Research Institute of Oncology, Krakow, Poland

ORLANDO, USA— A non-covalent inhibitor of Bruton’s tyrosine kinase looks superior to the current standard of care as initial therapy for patients with chronic lymphocytic leukemia. That’s in research from Poland reported at the 2025 American Society of Hematology Annual Meeting in which the randomized CLL/SLL (BRUIN CLL-313; NCT05023980) phase three study...

Gaorav Gupta MD PhD; SABCS 2025: Pre-Op Radiation Improved T-cell Infiltration in Hormone Receptor-positive, HER2-negative Invasive Breast Cancer; Could Boost Systemic Therapy Responses

An interview with:

Gaorav Gupta MD PhD, Associate Professor Radiation Oncology, University of North Carolina at Chapel Hill, North Carolina, USA

SAN ANTONIO, USA—Patients with the most common form of breast cancer could respond better to immunotherapy and chemotherapy if they received neo-adjuvant radiation therapy. This is the implication of findings from the TBCRC-053 (P-RAD) study in patients with hormone receptor-positive, HER2-negative breast cancer which found an increase of...

Bispecific Antibody Epcoritamab Combination Beats Standard of Care for Patients with Relapsed/Refractory Follicular Lymphoma

An interview with:

Lorenzo Falchi MD, Lymphoma Service, Attending Physician, Memorial Sloan Kettering Cancer Center, New York NY, USA

ORLANDO, USA—A bispecific antibody to treat follicular lymphoma has outperformed standard rituximab plus lenalidomide in patients whose disease has relapsed or who are refractory to standard first-line treatments.  This was in the phase three epcore FL-1 trial in which patients receiving rituximab and lenalidomide were randomly assigned to have the CD3xCD20 bispecific Epcoritamab or a placebo added to...

Denosumab Bone Protection in ER-Positive Early Breast Cancer Brings Added Benefit with Progesterone Receptor Positive Tumors: ABCSG 18 Study Findings

An interview with:

Christian F Singer MD, Professor of Clinical-Translational Gynecological Oncology, Medical University of Vienna, Austria

SAN ANTONIO, USA—Post-menopausal women treated with denosumab to give bone protection along with their aromatase inhibitor hormone therapy did better if their tumors tested positive for the progesterone receptor as well as for the estrogen receptor.  This is according to finding from the ABCSG 18 Study (of the Austrian Breast and Colorectal Cancer Study...

Amir Fathi MD; ASH 2025: Paradigm Study Finds Young, Fit Adults with Acute Myeloid Leukemia Do Better with Gentler Azacitidine/Venetoclax Initial Therapy

An interview with:

Amir Fathi MD, Leukemia Program Director, Massachusetts General Hospital and Associate Professor of Medicine, Harvard Medical School, Boston, USA.

ORLANDO, USA— Young, fit adults with acute myeloid leukemia had fewer toxicities and better response rates when treated with a combination of venetoclax plus azacytidine in comparison with similar group of patients who had standard induction chemotherapy.  This was in the Paradigm phase two multi center randomized study reported at...

Jennifer A. Woyach MD, ASH 2024: The Non-Covalent Bruton’s Tyrosine Kinase-Inhibitor Pirtobrutinib is As Effective, While Less Toxic, In Relapsed/Refractory Chronic Lymphocytic Leukemia

An interview with:

Jennifer A. Woyach MD, Director of Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, United States

ORLANDO, USA—The possibility of using a less toxic Bruton’s tyrosine kinase (BTK) inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma—especially in treatment naïve patients— could become a reality according to promising findings from the first randomized phase III study comparing a non-covalen...

Alexis Ann LeVee MD; 2025 SABCS: Pre-Operative Gut Microbiome Predicts Complete Response to Immune Checkpoint Inhibition in Patients with Early-stage HER2-positive Breast Cancer

An interview with:

Alexis Ann LeVee MD, Clinical Instructor of Medicine, UCLA David Geffen School of Medicine, Los Angeles, USA.

SAN ANTONIO,  USA—New evidence that what patients eat can have a strong influence on the effectiveness of their cancer treatment was illustrated by new research on the microbiome reported at the 2025  San Antonio Breast Cancer Symposium.

The conference saw results from the randomized phase II neoHIP trial look...

B-Cell Maturation Antigen Bispecific Antibody Linvoseltamab Brings High Response Rates in Patients with Relapsed/Refractory Multiple Myeloma

An interview with:

Meletios-Athanasios C. Dimopoulos MD, Professor and Chair, Department of Clinical Therapeutics (Alexandra Hospital), School of Medicine, University of Athens, Greece.

ORLANDO, USA—The bispecific monoclonal antibody linvoseltamab achieved high rates of clinical response when used in combination with anti-CD 38 therapy in patients who had relapsed/refractory multiple myeloma. Early findings on efficacy and safety from the phase 1b LINKER-MM2 trial were announced at the 2025 Annual Meeting of the American Society of Hematology by Me...

Antonio Jimenez Jimenez MD MS; ASH 2025: Donor Choice No Longer a Barrier to Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies

An interview with:

Antonio Jimenez Jimenez MD MS, Associate Professor of Medicine, Division of Transplantation and Cellular Therapy, University of Miami Miller School of Medicine, Sylvester Cancer Center, Co-Chair National Marrow Donor Program Access Trial, Miami, FL, United States

ORLANDO, USA—A wider, more ethnically diverse range of patients could safely receive allogeneic hematopoietic cell transplantations from unrelated donors according to findings from the USA-based National Marrow Donor Program Access Trial re...

Safna Naozer Virji MBBS FPBS; 2025 SABCS: Oncoplastic Breast Cancer Surgery Study Reports High Efficacy with Superior Psychosocial Outcomes in a Low or Middle Income Country Setting

 An interview with:

Safna Naozer Virji MBBS FPBS

Breast Surgery Fellow, Aga Khan University Hospital, Karachi  , Pakistan

SAN ANTONIO, USA—Breast cancer surgeons can deliver high levels of satisfaction to worried patients without sacrificing efficacy in resource-limited settings in a low or middle income country, according to research from Pakistan reported at the 2025 San Antonio Breast Cancer Symposium.

Safna Naozer Virji MBBS...

Luciano Costa, MD, PhD; ASH 2025:  CAR T Cell Brings Profound Benefit with Long-Term Progression-Free Survival in Patients with Standard-Risk Relapsed/Refractory Multiple Myeloma

An interview with:

Luciano Costa, MD PhD, University of Alabama at Birmingham, Birmingham, Alabama, United States

ORLANDO, USA—The CARTITUDE-4 study has f0und that patients with standard-risk relapsed or refractory multiple myeloma can benefit greatly from ciltacabtagene autoleucel CAR-T cell therapy after one to three prior lines of therapy, as do those with high-risk disease.  Study findings were reported at the American Society of Hematology 2025 Annual Meeting in Orlando Flor...

Matteo Lambertini MD PhD; San Antonio Breast Cancer Symposium: ALTTO Trial Shows Adjuvant Aromatase Inhibitors Outperform Tamoxifen in Patients with ER-Positive, HER2-Positive Early Breast Cancer  

An interview with:

Matteo Lambertini MD PhD, Assistant Professor, University of Genoa, Consultant in Medical Oncology, San Martino IST Hospital, Genoa, Italy.

SAN ANTONIO, USA­—Patients with hormone receptor positive HER2-positive early breast cancer had superior outcomes when treated with aromatase inhibitor adjuvant therapy than similar patients treated with adjuvant tamoxifen or other selective estrogen receptor modulators (SERMs).  This is the headline finding from a long-term analy...

ASH 2025: Measurable Residual Disease Can Predict Overall Survival in Patients with Acute Myeloid Leukemia

An interview with: Jesse Tettero MD PhD, Amsterdam University Medical Center, Department of Hematology, Amsterdam, Netherlands and: Virginia Tech FBRI Cancer Research Center, Fralin Biomedical Research Institute, Washington, USA.

Reporting from: American Society of Hematology 2025 Annual Meeting, Orlando, USA

ORLANDO, USA—Measurable residual disease (MRD) could soon emerge as a key surrogate endpoint in clinical studies of acute myeloid leukemia indicating overall survival, and speed the introduction of effective new agents. That’s according to findings from the HARMONY Alli...

Next Generation Sequencing-Assessed Minimum Residual Disease Identifies Young Patients with High-risk/Relapsed B-cell Acute Lymphoblastic Lymphomas Who Can Omit Pre-Transplant Total Body Irradiation

An interview with:

Hisham Abdel-Azim MD MS, Chief, Division of Transplant/Cell Therapy and Hematological Malignancies, Cancer Center, Departments of Pediatrics and Medicine, Loma Linda University School of Medicine, Children Hospital and Medical Center, Loma Linda CA, United States

ORLANDO, Florida—Total body irradiation before allogeneic hematopoietic cell transplantation can be avoided in patients with B-cell lymphomas if you monitor their initial treatment responses by assessing minimum residual disease using ne...

2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings

An interview with: Aditya Bardia MD MPH, Professor of Medicine and Director of Translational Research Integration, University of California, Los Angeles and Jonsson Comprehensive Cancer Center, Los Angeles, California USA.

SAN ANTONIO, USA—Significant and clinically meaningful improvements in disease-free survival were reported from the Phase III lidERA Breast Cancer trial at the 2025 San Antonio Breast Cancer Symposium, in San Antonio, USA.  First author of the...

ASH 2025 Orlando: Childhood Leukemia Cured But Families Broke. “Financial Toxicity” is Often More Worrying than you Child’s Cancer

An interview with: Daniel J Zheng MD, MHS, MSHP, Instructor, Children’s Hospital of Philadelphia, Attending Oncologist, Division of Oncology, Philadelphia PA, United States

ORLANDO, USA—Although most children with acute lymphoblastic leukemia can look forward to a cure, their families may face catastrophic financial hardship, according to Daniel Zheng, an Instructor and Attending Oncologist at the Division of Oncology, Children’s Hospital of Philadelphia in Philadelphia, PA, United States. After reporting on the challenge families face of “fin...

https://www.audiomedica.com/wp-content/2025/12/251209-0900-Peihua-Lu-Robert-Chiesa-C2998-Discussion-at-ASH-AJO-PRODUCTION-MASTER.mp3Dramatic Remissions with “Off-the-Shelf” and “Base Edited” CAR T-cell Therapies in Children with Relapsed/Refractory T-Cell Malignancies

A discussion interview with Peihua Lu MD from Lu Daopei Hospital in Beijing, China and Robert Chiesa MD PhD from Great Ormond Street Hospital for Children, London, UK, at the American Society of Hematology Annual Meeting in Orlando, Florida, USA

ORLANDO, USA—Children and young adults whose T-cell malignancies had become refractory to all standard treatments have been rescued by means of two different chimeric antigen receptor T-cell therapies: one develo...

An interview with Jeanne Tie MD, Medical Oncologist, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.

BERLIN, Germany—Liquid biopsy as a means of monitoring disease control in patients with stage three colon cancer has been investigated in a study from Melbourne, Australia reported to the 2025 Annual Congress of the European Society for Medical Oncology, ESMO. The aim was to discover whether patients with ctDNA negative biopsy findings could safely avoid chemotherapy and be spared toxicities including neuropathy.

After reporting findings from the AGITG DYNAMIC-III tr...

Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer

An interview with: Paul H Cottu MD PhD, Medical Oncologist and Associate Professor, Institute Curie, Paris, France

BERLIN, Germany—Patients with high-risk, hormone receptor positive, HER2 negative early breast cancers, who would typically be candidates for chemotherapy, had good clinical responses, high biological responses and good rates of surgery in a clinical trial using a chemotherapy-free neoadjuvant regimen consisting of letrozole hormone therapy plus abemaciclib CDK 4/6 inhibition.

Medical Oncologist Paul Cottu MD PhD from th...

An interview with Li Zhang MD, Medical Oncologist and Full Professor, Sun Yat-sen University Cancer Center, Guangzhou, China

BERLIN, Germany—A doubling of progression-free survival, and highly statistically significant benefit for overall survival, has been achieved in patients with epidermal growth factor- (EGFR-) mutated non-small cell lung cancers that had become refractory to EGFR tyrosine kinase inhibitor therapy in a study in which treatment with the antibody drug conjugate (ADC) sacituzumab tirumotecan was compared with standard platinum-based chemotherapy.

At the 2025 Annual Congress of the European Society for Medical Oncology (ESMO) Professor Li Zhang MD, a me...

An interview with: https://www.audiomedica.com/wp-content/2025/11/251019-Erwei-Song-ESMO-2025-PRODUCTION-MASTER.mp3, Director of Health Science Center, President, Sun Yat-sen Memorial Hospital, Guangzhou (SYSU), Guangzhou, China.

BERLIN, Germany—The open-label HORIZON-Breast01 phase-three study has reported early data showing that, for previously treated patients with advanced or metastatic breast cancer, progression-free survival improved from a median of 8.3 months with pyrotinib plus capecitabine standard of care to 30.6 months among patients in the experimental arm who received monotherapy with the new antibody drug conjugate (ADC) trastuzumab resetecan. Furthermore, the ADC had a favorable safety profile with low occurrence of interstitial lung di...

An interview with: Andrew Clamp MD, PhD, Consultant Medical Oncologist, Christie Hospital, Manchester, UK

BERLIN, Germany—An important therapeutic gain in terms of overall- and progression-free survival has been achieved merely by changing the chemotherapy dose schedule given to patients with high-risk stage three or four epithelial ovarian cancer.

This was reported from the ICON8B: GCIG phase-three randomised trial by Andrew Clamp MD PhD of the Christie Hospital in Manchester, England, at the 2025 Annual Congress of the European Society for Medical Oncology. Dr. Clamp discussed the findings with our reporter, Peter Goodwin.

Au...

An interview with Nima Nabavizadeh MD, Associate Professor of Radiation Medicine, Oregon Health & Science University (OHSU), Portland, USA, Chief Medical Officer, Cancer Early Detection Research Center, Portland, Oregon.https://www.audiomedica.com/wp-content/2025/11/251107-Nima-Nabavizadeh-MD-ESMO-2024-PRODUCTION-MASTER.mp3

BERLIN, Germany—A pan-cancer early detection test, that identifies “methylation fingerprints” for a wide range of cancers, has been shown to find more cancers sooner than conventional screening according to research reported to the European Society for Medical Oncology (ESMO) 2025 Annual Congress.

Nima Nabavizadeh MD, Associate Professor of Radiation Medicine at the Oregon Health & Science University (OHSU) in Portland, USA, w...

An interview with: Xiuning Le MD PhD, Medical Oncologist, Department of Thoracic Medicine, UT MD Anderson Cancer Center, Houston TX

BERLIN, Germany—Mutations in the HER2 molecule can be found in a few per cent of non-small cell lung cancers, and these can now be targeted by the new drug sevabertinib that can bring benefit to patients who have the mutation. That’s according to findings from the SOHO-01 study reported at the 2025 Annual Congress of the European Society of Clinical Oncology.

After her talk at the congress, first author Xiuning Le MD PhD, who is a...

An interview with: Christof Vulsteke MD PhD, Medical Oncologist, Head of the Integrated Cancer Center Ghent, Belgium

BERLIN, Germany—Patients with muscle invasive bladder who were ineligible for cisplatin chemotherapy gained large, clinically meaningful and statistically significant benefits from treatment with the antibody drug conjugate enfortumab vedotin combined with pembrolizumab checkpoint inhibition in the phase three KEYNOTE-905 study.

At the 2025 Annual Congress of the European Society for Medical Oncology (ESMO) Medical Oncologist Christof Vulsteke, Head of the Integrated Cancer Centre in Ghent, Belgium, reported marked improvements of event-free and overall survival among patients treated with th...

An interview with: Xichun Hu MD PhD, Professor, Director, Department of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China

BERLIN, Germany—In a head-to-head comparison of two antibody drug conjugates used to treat unresectable or metastatic breast cancer, patients treated with trastuzumab botidotin lived more than twice as long before disease progression than those in the control arm receiving trastuzumab emtansine (T-DM1).  This finding was announced by Chinese researchers at the 2025 Annual Congress of the European Society of Medical Oncology.

Lead author Xichun Hu MD PhD, Professor, Director, Department of Medical Oncology, Shanghai Cancer Cen...

An interview with: Martin Wermke MD, TU Dresden, NCT/UCC Early Clinical Trial Unit and Medical Clinic, Poliklinik I, Natural Centre for Tumor Diseases, Dresden, Germany

BERLIN, Germany—The prospect of markedly better outcomes for patients with small cell lung cancer, with “encouraging initial survival outcomes”, was raised by findings from the DeLLphi-303 study, reported at the European Society for Medical Oncology (ESMO) 2025 Annual Congress. The bi-specific T-cell engager drug tarlatamab was included with initial therapy for patients with extensive stage small cell lung cancer.

Martin Wermke MD, from TU Dresden, Director of the NCT/UCC Ea...

An interview with:  John P. Crown MD MBA, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin, Professor of Translational Cancer Research, Dublin City University, Professor of Medicine, University College Dublin   Ireland.

BERLIN, Germany—Patients with high-risk node-negative ER-positive HER2-negative early breast cancer who had the CDK 4/6 inhibitor drug ribociclib added to their non-steroidal aromatase inhibitor (AI) adjuvant therapy after surgery had significantly longer freedom from progression to invasive disease compared with patients receiving the AI alone.  This is according to five-year data from the NATALEE trial reported at the 2025 Annual Congress of the European Society for Medi...

An interview with: Javier C Cortés MD PhD, Breast Cancer Medical Oncologist, IOB Madrid, Institute of Oncology, Madrid, and International Breast Cancer Centre, Barcelona, Spain

BERLIN, Germany—Treatment with the antibody drug conjugate (ADC) sacituzumab govitecan (that targets the Trop-2 cancer-associated protein, delivering a cytotoxic topoisomerase inhibitor payload) has significantly improved progression-free survival in patients with newly-diagnosed metastatic triple-negative breast cancer who were not candidates for treatment with immune checkpoint inhibition and had received no prior therapy.

At the European Society for Medical Oncology (ESMO) 2025 Annual Congress Javier C Cortés MD PhD from the...

An interview with:

Trevor Leong  MD, Peter McCallum Cancer Centre, Radiation Oncology Department, Melbourne, Australia

BARCELONA, Spain—Although pre-operative radiotherapy brought better response rates in patients resected for their gastric or GE-junction adenocarcinomas, there was no improvement in survival. This is the clear finding from a big, long-term study led by an Australian team.

The multi-continent, phase-three randomized TOP GEAR trial, headquartered in Sydney Australia, definitively found no benefit for overall or progression-free survival from adding radiation before surgery.

This clear finding was announced at the 2024 Annual Meeti...

An interview with: Domenica Lorusso MD PhD, Director of the Gynaecological Oncology Unit, full Professor of Obstetrics and Gynaecology, Humanitas Hospital San Pio X, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.

Both overall and progression-free survival were significantly improved when the anti-PD-1 agent pembrolizumab was added to standard chemoradiotherapy as initial treatment for patients with high-risk locally advanced cervical cancer.

Results from the randomized, double-blind, phase III KEYNOTE-A18 study of immunotherapy, used together with standard concurrent chemoradiotherapy among 1060 patients, were reported by a multinational team of researchers led...

An interview with:

James Larkin FRCP, PhD, Medical Oncologist, Professor, Royal Marsden Hospital, London

Checkpoint inhibitor therapy for advanced melanoma has achieved sustained responses and long-term overall survival, transforming the prognosis for as many as half of all patients. 10-year survival outcomes from the phase Ill CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma were reported at the 2024 Annual Meeting of the European Society for Medical Oncology (ESMO) held in Barcelona.

Peter Goodwin, talked with study author, James Larkin FRCP PhD, Professor and Medical Oncologist at the Royal Marsden Hospital in London.<...

An interview with: Jefferson DeKloe BSc, Department of Otolaryngology, Thomas Jefferson University, Philadelphia, PA

CHICAGO, USA—Although the take-up of vaccination for human papilloma virus (HPV) among girls and boys in the USA has been lower than in many other industrial countries, American researchers have now shown clearly that in addition to the prevention of cervical cancer in women, men have also been protected against HPV-related cancers.

At the 2024 American Society of Clinical Oncology Annual (ASCO) Meeting in Chicago a new study of HPV vaccination of girls and boys in the United States revealed a re...

An interview with Rebecca Dent MD, Deputy Chief Executive Officer, National Cancer Centre, Singapore, ESMO 2024 Scientific Chair.

ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……”

BARCELONA, Spain—At the last Annual Meeting of the European Society for Medical Oncology (ESMO), medical oncologist Rebecca Dent MD, Deputy Chief Executive Officer at the National Cancer Centre in Singapore, told Peter Goodwin what had, for her, been the key areas of progress in cancer medicine announced at the meeting in which significant advances had been made.

Audio Journal...